Research Article
Serum Cholinesterases, a Novel Marker of Clinical Activity in Inflammatory Bowel Disease: A Retrospective Case-Control Study
Table 1
Characteristics of patients with IBD and HCs.
| Subjects | Patients with CD () | Patients with UC () | Healthy controls () |
| Male/female () | 39/21 | 56/86 | 170/94 | Age (yr) | | | | ChE (U/L) | | | | CRP (mg/L) | | | / | ALB (g/L) | | | | PLT (109/L) | | | | Ca2+ (mmol/L) | | | | Body mass index (kg/m2) | | | | Medications, (%) | | | | 5-ASA | 42 (70%) | 108 (76%) | / | Antibiotics | 5 (8.3%) | 22 (15.5%) | / | Steroids | 13 (21.7%) | 36 (25.3%) | / | Immunosuppression | 8 (13%) | 13 (9.2%) | / | Biological therapy | 18 (30%) | 4 (2.8%) | / |
|
|
Data shown as .CD: Crohn’s disease; UC: ulcerative colitis; ChE: cholinesterases; CRP: C-reactive protein; ALB: albumin; PLT: platelets. |